--- title: "MeiraGTx Holdings (MGTX) news: merger" url: "https://aibio.space/companies/meiragtx/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "MGTX merger news: MeiraGTx agrees to buy bota-vec from Johnson & Johnson for $25 million upfront. MeiraGTx Holdings plc (NASDAQ: MGTX), United States." --- MGTX MeiraGTx Holdings plc NASDAQ · United States # MeiraGTx Holdings (MGTX) news MGTX merger news Financings · 2026-07-07 ## [MeiraGTx agrees to up to $400 million Oberland Capital investment, $135 million initially](https://aibio.space/news/meiragtx-agrees-up-400-million-oberland-capital-investment-135-million/) MeiraGTx will receive up to $400 million from Oberland Capital, starting with $135 million that includes $125 million of royalty funding and a $10 million equity investment. The release does not state the cap multiple on the royalties or the price of the new shares. ## Latest MeiraGTx Holdings news 1. 2026-04-16 Mergers [MeiraGTx buys XLRP gene therapy rights from Janssen for $25,000,000 upfront](https://aibio.space/news/meiragtx-buys-xlrp-gene-therapy-rights-janssen-25-000-000-upfront/) MeiraGTx also agreed to a one-time $50,000,000 contingent payment and mid-teens royalties starting on or after July 1, 2029. The 8-K also reports an amendment with Hologen. 2. 2026-04-16 Mergers [MeiraGTx agrees to buy bota-vec from Johnson & Johnson for $25 million upfront](https://aibio.space/news/meiragtx-agrees-buy-bota-vec-johnson-johnson-25-million-upfront/) MeiraGTx will pay Johnson & Johnson $25 million in cash upfront for bota-vec, a gene therapy whose Phase 3 primary endpoint did not reach statistical significance. The company plans filings in the U.S., EU and Japan, with a potential launch in 2027. 3. 2026-03-26 Financings [MeiraGTx extends Perceptive notes to May 2027, agrees to redeem $25,000,000](https://aibio.space/news/meiragtx-extends-perceptive-notes-may-2027-agrees-redeem-25-000-000/) MeiraGTx (Nasdaq: MGTX) moved the maturity of its Perceptive notes from August 2, 2026 to May 2, 2027. It will redeem $25,000,000 by June 30, 2026, and Perceptive's warrants are repriced to $8.00. 4. 2025-04-04 Distress [MeiraGTx signs new New York lab lease and ends sublease early](https://aibio.space/news/meiragtx-signs-new-new-york-lab-lease-ends-sublease-early/) MeiraGTx will pay base rent of $111.00 per square foot a year on a new 14,235 square foot lab at 450 East 29th Street, and it moved to end its current sublease at the same address earlier than scheduled. The 8-K does not say what the total commitment will cost. ## MeiraGTx Holdings at a glance - **Ticker**: MGTX - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $143.2 million ### Related companies - [Longeveron](https://aibio.space/companies/longeveron/) NASDAQ: LGVN - [Dyne Therapeutics](https://aibio.space/companies/dyne-therapeutics/) NASDAQ: DYN - [MetaVia](https://aibio.space/companies/metavia/) NASDAQ: MTVA - [Contineum Therapeutics](https://aibio.space/companies/contineum-therapeutics/) NASDAQ: CTNM - [Alector](https://aibio.space/companies/alector/) NASDAQ: ALEC - [CERo Therapeutics Holdings](https://aibio.space/companies/cero-therapeutics/) OTC: CERO - [Filana Therapeutics](https://aibio.space/companies/filana-therapeutics/) NASDAQ: FLNA - [Atrium Therapeutics](https://aibio.space/companies/atrium-therapeutics/) NASDAQ: RNA ### Also on NASDAQ - [BRUKER CORP](https://aibio.space/companies/bruker/) BRKR - [Annexon](https://aibio.space/companies/annexon/) ANNX - [Iambic Therapeutics](https://aibio.space/companies/iambic-therapeutics/) IAM - [Aclaris Therapeutics](https://aibio.space/companies/aclaris-therapeutics/) ACRS - [BioNexus Gene Lab](https://aibio.space/companies/bionexus-gene-lab/) BGLC - [Hyperfine](https://aibio.space/companies/hyperfine/) HYPR ## What MeiraGTx Holdings does MeiraGTx Holdings is a vertically integrated, clinical-stage genetic medicines company. Its clinical programs use targeted local delivery of small doses of genetic medicines to treat inherited and more common conditions. Its late-stage programs include radiation-induced xerostomia, Parkinson's disease and AIPL1-associated retinal dystrophy. Its riboswitch platform uses bespoke synthetic riboswitch technology invented in-house to allow precise, dose-responsive expression of a transgene under the control of oral small molecules. The company is focusing that platform on in vivo delivery of biologic therapeutics such as the metabolic peptides GLP-1, GIP, glucagon, amylin, PYY and leptin, as well as cell therapy for oncology and autoimmune diseases and long-term intractable pain. It operates viral vector production facilities in London, United Kingdom and Shannon, Ireland. In December 2025, its London facility was granted a commercial Manufacturer's and Importer's Authorization by the Medicines and Healthcare products Regulatory Agency for advanced therapy medicinal products. The company has a collaboration, option and license agreement with Johnson & Johnson Innovative Medicine, entered on January 30, 2019. | Product or program | What it is | Stage | |---|---|---| | Radiation-induced xerostomia program | Targeted local genetic medicine for radiation-induced xerostomia | Late-stage clinical | | Parkinson's disease program | Targeted local genetic medicine for Parkinson's disease | Late-stage clinical | | AIPL1-associated retinal dystrophy program | Targeted local genetic medicine for AIPL1-associated retinal dystrophy | Late-stage clinical | Summarised from the company's [10-K filed Mar 30, 2026](https://www.sec.gov/Archives/edgar/data/1735438/000110465926036494/mgtx-20251231x10k.htm). ## MeiraGTx Holdings annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$81.4 million](https://www.sec.gov/Archives/edgar/data/1735438/000110465926036494/) | [$33.3 million](https://www.sec.gov/Archives/edgar/data/1735438/000110465926036494/) | | Research and development | [$129.6 million](https://www.sec.gov/Archives/edgar/data/1735438/000110465926036494/) | [$119.5 million](https://www.sec.gov/Archives/edgar/data/1735438/000110465926036494/) | | Net income (loss) | [-$114.2 million](https://www.sec.gov/Archives/edgar/data/1735438/000110465926036494/) | [-$147.8 million](https://www.sec.gov/Archives/edgar/data/1735438/000110465926036494/) | | Cash from operations | [-$46.4 million](https://www.sec.gov/Archives/edgar/data/1735438/000110465926036494/) | [-$104.5 million](https://www.sec.gov/Archives/edgar/data/1735438/000110465926036494/) | | Cash and equivalents | [$65.9 million](https://www.sec.gov/Archives/edgar/data/1735438/000110465926095504/) | [$103.7 million](https://www.sec.gov/Archives/edgar/data/1735438/000110465926036494/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $143.2 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about MeiraGTx Holdings Is MeiraGTx Holdings involved in a merger or acquisition? Our latest story on this, dated Apr 16, 2026: "MeiraGTx agrees to buy bota-vec from Johnson & Johnson for $25 million upfront". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/meiragtx-agrees-buy-bota-vec-johnson-johnson-25-million-upfront/). What is the ticker symbol of MeiraGTx Holdings? MeiraGTx Holdings plc trades under the ticker MGTX on NASDAQ. Where is MeiraGTx Holdings listed? MeiraGTx Holdings plc is listed on NASDAQ. Our directory also records these other listings: GETTEX:328; LS:A2JGHF. What is the SEC CIK of MeiraGTx Holdings? The SEC Central Index Key (CIK) for MeiraGTx Holdings plc is 1735438. Its filings are on SEC EDGAR. How many shares does MeiraGTx Holdings have outstanding? 96,042,996 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-13. Which country or territory is MeiraGTx Holdings listed under? Our directory records MeiraGTx Holdings plc under United States. What does MeiraGTx Holdings do? Our directory classifies MeiraGTx Holdings plc as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of MeiraGTx Holdings? The ISIN recorded for MeiraGTx Holdings plc is KYG596651029. Does aibio.space cover MeiraGTx Holdings? aibio.space lists MeiraGTx Holdings plc among 2,820 public biotech companies and publishes its news here as stories appear. What does MeiraGTx Holdings develop? MeiraGTx Holdings is a vertically integrated, clinical-stage genetic medicines company. Its clinical programs use targeted local delivery of small doses of genetic medicines to treat inherited and more common conditions. What is Radiation-induced xerostomia program from MeiraGTx Holdings? Radiation-induced xerostomia program: Targeted local genetic medicine for radiation-induced xerostomia Stage: Late-stage clinical. What is Parkinson's disease program from MeiraGTx Holdings? Parkinson's disease program: Targeted local genetic medicine for Parkinson's disease Stage: Late-stage clinical. What was MeiraGTx Holdings's revenue last year? $81.4 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is MeiraGTx Holdings profitable? MeiraGTx Holdings plc reported a net loss of $114.2 million for the fiscal year ended Dec 31, 2025, and used $46.4 million of cash in operations, per its annual report to the SEC. How much does MeiraGTx Holdings spend on research and development? $129.6 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: MeiraGTx Holdings Members talk about MeiraGTx Holdings (MGTX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at MeiraGTx Holdings, newest first. Each line links the filing it comes from. 1. 2026-07-07 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,1.02,2.03,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1735438/000110465926080949/mgtx-20260630xex99d1.htm) 2. 2026-04-16 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,1.02,2.01,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1735438/000110465926044028/mgtx-20260415xex99d1.htm) 3. 2026-04-16 Financings Filed a final prospectus for a securities offering. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1735438/000110465926044464/tm2612020-1_424b5.htm) 4. 2025-04-04 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.01,1.02). [Source](https://www.sec.gov/Archives/edgar/data/1735438/000155837025004490/mgtx-20250331x8k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:MGTX on TradingView](https://www.tradingview.com/symbols/NASDAQ-MGTX/). ## SEC filings and registration - **SEC name**: MeiraGTx Holdings plc - **CIK**: 1735438 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: MGTX (Nasdaq) - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 655 THIRD AVENUE, NEW YORK, NY, 10017 - **Phone**: 646-860-7985 - **Shares outstanding**: 96,042,996 as of 2026-08-11 (10-Q filed 2026-08-13) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1735438/000110465926109824/mgtx-20260922x8k.htm) filed 2026-09-23 - [10-Q](https://www.sec.gov/Archives/edgar/data/1735438/000110465926095504/mgtx-20260630x10q.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1735438/000110465926095491/mgtx-20260813x8k.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1735438/000110465926080949/mgtx-20260630x8k.htm) filed 2026-07-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1735438/000110465926074085/mgtx-20260611x8k.htm) filed 2026-06-15 - [10-Q](https://www.sec.gov/Archives/edgar/data/1735438/000110465926060739/mgtx-20260331x10q.htm) filed 2026-05-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1735438/000110465926060726/mgtx-20260514x8k.htm) filed 2026-05-14 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1735438/000110465926052190/mgtx-20260611xdef14a.htm) filed 2026-04-30 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001735438), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details MeiraGTx Holdings plc is a public biotech or pharmaceutical company listed on NASDAQ under the ticker MGTX, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: MeiraGTx Holdings plc - **Ticker**: MGTX - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: KYG596651029 - **Other listed symbols**: GETTEX:328; LS:A2JGHF - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-MGTX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/meiragtx/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "MeiraGTx Holdings (MGTX) news: merger", 2026-10-31, https://aibio.space/companies/meiragtx/